Johnson & Johnson (JNJ)
-NYSE 88.46 
0.13(0.15%) 21:01|After Hours:
:
88.35 0.11 (0.13%) 21:28 - Nasdaq Real Time Price
| Prev Close: | 88.59 |
|---|
| Open: | 88.70 |
|---|
| Bid: | 88.36 x 100 |
|---|
| Ask: | 88.44 x 200 |
|---|
| 1y Target Est: | 86.50 |
|---|
| Beta: | 0.48 |
|---|
| Next Earnings Date: | 15-Jul-13 |
|---|
| Day's Range: | 88.20 - 89.99 |
|---|
| 52wk Range: | 61.71 - 89.99 |
|---|
| Volume: | 13,795,877 |
|---|
| Avg Vol (3m): | 9,717,350 |
|---|
| Market Cap: | 248.47b |
|---|
| P/E (ttm): | 24.02 |
|---|
| EPS (ttm): | 3.68 |
|---|
| Div & Yield: | 2.64 (3.00%) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Insight - Dimon has big say over who serves on JPMorgan boardReuters(Thu 16 May)
- REUTERS SUMMIT-Faster drug approvals a tonic for pharma industryReuters - UK Focus(Wed 8 May)
- MARKET PULSE-Cliffs, Apollo Global, BMC, Intel, Yum, Tyson FoodsReuters - UK Focus(Mon 6 May)
- MARKET PULSE-Apollo Global, BMC, Verizon, Intel, MicrosoftReuters - UK Focus(Mon 6 May)
- US STOCKS-Dow, S&P 500 close at record levels after jobs reportReuters - UK Focus(Fri 3 May)
- US STOCKS-Dow, S&P 500 surge to records after U.S. payrolls reportReuters - UK Focus(Fri 3 May)
- UPDATE 1-Smith & Nephew unveils $300 mln share buybackReuters - UK Focus(Thu 2 May)
- Money MOT: Old Mutual US Dividend fundTelegraph(Thu 25 Apr)
- UPDATE 2-Elan tees up deals as sales of prized drug rise sharplyReuters - UK Focus(Wed 24 Apr)
- Elan rejects Royalty bid as grossly undervaluing its prospectsReuters(Mon 22 Apr)
Key Statistics
| Forward P/E (1 yr): | 15.30 |
|---|
| P/S (ttm): | 3.63 |
|---|
| Ex-Dividend Date: | 23-May-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 5.41 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.39 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 2.56 |
|---|
Business Summary
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide.
more 